MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

ONC.US

244.1

-0.91%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

ONC.US

244.1

-0.91%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

ONC.US

244.1

-0.91%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

ONC.US

244.1

-0.91%↓

MRK1

116.2

+1%↑

SHL.DE

46.58

-0.98%↓

ARGX

505.8

-1.21%↓

FRE

43.06

+1.25%↑

ONC.US

244.1

-0.91%↓

Search

Sanofi SA

Chiusa

SettoreSettore sanitario

87.36 -5.12

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

87.14

Massimo

87.68

Metriche Chiave

By Trading Economics

Entrata

1.4B

1.9B

Vendite

3B

11B

P/E

Media del settore

18.595

53.54

EPS

1.79

Rendimento da dividendi

4.25

Margine di Profitto

17.65

Dipendenti

82,878

EBITDA

2.2B

2.8B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+32.37% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

4.25%

2.44%

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-15B

115B

Apertura precedente

92.48

Chiusura precedente

87.36

Notizie sul Sentiment di mercato

By Acuity

42%

58%

130 / 381 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Sanofi SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 mag 2025, 12:02 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22 mag 2025, 00:06 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vigil Neuroscience for About $470 Million

5 mag 2025, 11:29 UTC

Acquisizioni, Fusioni, Takeovers

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- 2nd Update

5 mag 2025, 09:09 UTC

Acquisizioni, Fusioni, Takeovers

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- Update

5 mag 2025, 07:25 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group to Buy Santander Assets in Poland for $7.91 Billion

30 mag 2025, 08:58 UTC

Azioni calde

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 mag 2025, 08:56 UTC

Discorsi di Mercato

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27 mag 2025, 05:03 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27 mag 2025, 05:00 UTC

Acquisizioni, Fusioni, Takeovers

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21 mag 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mag 2025, 23:23 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mag 2025, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mag 2025, 23:20 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mag 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

19 mag 2025, 11:01 UTC

Discorsi di Mercato

Diversified Exposure to European Banks Is Required -- Market Talk

15 mag 2025, 11:04 UTC

Discorsi di Mercato
Utili

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

13 mag 2025, 12:53 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Natwest's Reported Santander UK Interest Seems Surprising -- Market Talk

13 mag 2025, 10:23 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Santander's Geographic Refocusing Can Lift Earning Estimates -- Market Talk

13 mag 2025, 08:58 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Any Sale of Santander UK Would Need Strong Justification -- Market Talk

12 mag 2025, 12:07 UTC

Discorsi di Mercato

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8 mag 2025, 17:55 UTC

Utili

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8 mag 2025, 15:12 UTC

Utili

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

6 mag 2025, 06:16 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Santander's Polish Business Disposal Is Attractive -- Market Talk

6 mag 2025, 06:13 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Erste's Cash Deal for Santander Bank Polksa Seen as Positive -- Market Talk

5 mag 2025, 14:11 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Erste Group Adds Exposure to Fast-Growing Polish Market, But Could Face Risk -- Market Talk

5 mag 2025, 11:30 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Sale of Polish Business Strengthens Santander's Capital Position -- Market Talk

5 mag 2025, 06:48 UTC

Acquisizioni, Fusioni, Takeovers

Santander Intends to Take Full Ownership of Santander Consumer Bank Polska

5 mag 2025, 06:48 UTC

Acquisizioni, Fusioni, Takeovers

Santander Will Own 13% of Santander Polska Following Transaction

Confronto tra pari

Modifica del prezzo

Sanofi SA Previsione

Obiettivo di Prezzo

By TipRanks

32.37% in crescita

Previsioni per 12 mesi

Media 115.848 EUR  32.37%

Alto 127 EUR

Basso 95 EUR

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sanofi SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

15 ratings

11

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

91.3 / 96.1Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

130 / 381 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.